Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline Review, H2 2016’, provides an overview of the Ebolavirus Infections (Ebola Hemorrhagic Fever) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Ebolavirus Infections (Ebola Hemorrhagic Fever) , complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Ebolavirus Infections (Ebola Hemorrhagic Fever) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Ebolavirus Infections (Ebola Hemorrhagic Fever)

The report reviews pipeline therapeutics for Ebolavirus Infections (Ebola Hemorrhagic Fever) by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Ebolavirus Infections (Ebola Hemorrhagic Fever) therapeutics and enlists all their major and minor projects

The report assesses Ebolavirus Infections (Ebola Hemorrhagic Fever) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Ebolavirus Infections (Ebola Hemorrhagic Fever)

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Ebolavirus Infections (Ebola Hemorrhagic Fever)

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Ebolavirus Infections (Ebola Hemorrhagic Fever) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Abivax SA

AnGes MG Inc

ANP Technologies Inc

Arno Therapeutics Inc

BioCryst Pharmaceuticals Inc

BioFactura Inc

Celgene Corp

Emergent BioSolutions Inc

Enyo Pharma SAS

Etubics Corp

GeoVax Labs Inc

Gilead Sciences Inc

GlaxoSmithKline Plc

Hemispherx Biopharma Inc

Humabs BioMed SA

Immune Response BioPharma Inc

Immunovaccine Inc

Inovio Pharmaceuticals Inc

Integrated BioTherapeutics Inc

Johnson & Johnson

Kineta Inc

Kymab Ltd

Medicago Inc

Merck & Co Inc

Microbiotix Inc

Micropharm Ltd

NanoViricides Inc

Navigen Pharmaceuticals, Inc.

Novavax Inc

Peregrine Pharmaceuticals Inc

Phelix Therapeutics LLC

PlantForm Corp

Profectus BioSciences Inc

RedHill Biopharma Ltd

Regeneron Pharmaceuticals Inc

Rodos BioTarget GmbH

SignPath Pharma Inc

Sirnaomics Inc

Soligenix Inc

Taiga Biotechnologies Inc

Tamir Biotechnology Inc

TGV-Laboratories

Toyama Chemical Co Ltd

Vaxart Inc

XBiotech Inc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 7

List of Figures 9

Introduction 10

Global Markets Direct Report Coverage 10

Ebolavirus Infections (Ebola Hemorrhagic Fever) Overview 11

Therapeutics Development 12

Pipeline Products for Ebolavirus Infections (Ebola Hemorrhagic Fever) - Overview 12

Pipeline Products for Ebolavirus Infections (Ebola Hemorrhagic Fever) - Comparative Analysis 13

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Therapeutics under Development by Companies 14

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Therapeutics under Investigation by Universities/Institutes 18

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline Products Glance 19

Late Stage Products 19

Clinical Stage Products 20

Early Stage Products 21

Unknown Stage Products 22

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Products under Development by Companies 23

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Products under Investigation by Universities/Institutes 28

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Companies Involved in Therapeutics Development 29

Abivax SA 29

AnGes MG Inc 30

ANP Technologies Inc 31

Arno Therapeutics Inc 32

BioCryst Pharmaceuticals Inc 33

BioFactura Inc 34

Celgene Corp 35

Emergent BioSolutions Inc 36

Enyo Pharma SAS 37

Etubics Corp 38

GeoVax Labs Inc 39

Gilead Sciences Inc 40

GlaxoSmithKline Plc 41

Hemispherx Biopharma Inc 42

Humabs BioMed SA 43

Immune Response BioPharma Inc 44

Immunovaccine Inc 45

Inovio Pharmaceuticals Inc 46

Integrated BioTherapeutics Inc 47

Johnson & Johnson 48

Kineta Inc 49

Kymab Ltd 50

Medicago Inc 51

Merck & Co Inc 52

Microbiotix Inc 53

Micropharm Ltd 54

NanoViricides Inc 55

Navigen Pharmaceuticals, Inc. 56

Novavax Inc 57

Peregrine Pharmaceuticals Inc 58

Phelix Therapeutics LLC 59

PlantForm Corp 60

Profectus BioSciences Inc 61

RedHill Biopharma Ltd 62

Regeneron Pharmaceuticals Inc 63

Rodos BioTarget GmbH 64

SignPath Pharma Inc 65

Sirnaomics Inc 66

Soligenix Inc 67

Taiga Biotechnologies Inc 68

Tamir Biotechnology Inc 69

TGV-Laboratories 70

Toyama Chemical Co Ltd 71

Vaxart Inc 72

XBiotech Inc 73

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Therapeutics Assessment 74

Assessment by Monotherapy Products 74

Assessment by Combination Products 75

Assessment by Target 76

Assessment by Mechanism of Action 78

Assessment by Route of Administration 80

Assessment by Molecule Type 82

Drug Profiles 84

(Ebola + Marburg) (monovalent) vaccine - Drug Profile 84

(Ebola + Marburg) (trivalent) vaccine - Drug Profile 86

(Ebola + Marburg) vaccine - Drug Profile 88

(Ebola [Sudan, Zaire] + Marburg) vaccine - Drug Profile 89

(Ebola [Sudan] + Marburg) vaccine - Drug Profile 93

(Ebola [Zaire] + rabies) (bivalent) vaccine - Drug Profile 94

(REGN-3470 + REGN-3471 + REGN-3479) - Drug Profile 95

1-E703 - Drug Profile 96

ABX-544 - Drug Profile 97

ANP-015 - Drug Profile 98

Antibodies for Ebola and Marburg Viral Infections - Drug Profile 99

Antibody for Ebola Viral Infection - Drug Profile 100

AR-12 - Drug Profile 101

ARD-5 - Drug Profile 104

bavituximab - Drug Profile 105

CC-11050 - Drug Profile 120

cosfroviximab + larcaviximab + porgaviximab - Drug Profile 121

DEF-201 - Drug Profile 124

DLANA-14 - Drug Profile 126

DPX-Ebola - Drug Profile 127

Drug for Ebola Virus Infection - Drug Profile 128

Drugs to Inhibit Cathepsin B for Ebola Viral Infections - Drug Profile 129

Ebola (virus like particle) vaccine - Drug Profile 130

Ebola [Zaire] (monovalent) vaccine - Drug Profile 131

Ebola [Zaire] vaccine - Drug Profile 133

Ebola [Zaire] vaccine - Drug Profile 138

Ebola [Zaire] vaccine - Drug Profile 139

Ebola [Zaire] vaccine - Drug Profile 140

Ebola [Zaire] vaccine - Drug Profile 142

Ebola [Zaire] vaccine - Drug Profile 144

Ebola [Zaire] vaccine - Drug Profile 145

Ebola vaccine - Drug Profile 146

Ebola vaccine - Drug Profile 147

Ebola vaccine - Drug Profile 148

Ebola vaccine - Drug Profile 149

Ebola vaccine - Drug Profile 150

Ebola vaccine - Drug Profile 151

Ebola vaccine - Drug Profile 152

EBOTAb - Drug Profile 153

favipiravir - Drug Profile 154

FBH-004 - Drug Profile 157

FDX-000 - Drug Profile 158

Fibrinoplate-S - Drug Profile 159

galidesivir - Drug Profile 160

Gene Therapy for Ebola Virus Infections - Drug Profile 163

GOVXE-301 - Drug Profile 164

GOVXE-302 - Drug Profile 165

GreEMTri - Drug Profile 166

GS-5734 - Drug Profile 167

imatinib mesylate - Drug Profile 168

ImmunoRx - Drug Profile 169

INO-4212 - Drug Profile 170

interferon alfa-n3 - Drug Profile 172

IRE-101 - Drug Profile 176

KIN-1400 - Drug Profile 177

KV-7005 - Drug Profile 179

Lalistat - Drug Profile 180

Lipocurc - Drug Profile 181

mAb-100 - Drug Profile 183

mAb-114 - Drug Profile 184

MB-003 - Drug Profile 185

MBX-2806 - Drug Profile 186

MIL-77 - Drug Profile 187

Monoclonal Antibodies 1 for Ebolavirus Infections - Drug Profile 188

Monoclonal Antibodies 2 for Ebolavirus Infections - Drug Profile 189

Monoclonal Antibodies for Ebola and Marburg Infections - Drug Profile 190

Monoclonal Antibodies for Ebola Viral Infections - Drug Profile 191

Monoclonal Antibodies for Viral Infections - Drug Profile 192

Monoclonal Antibodies to Inhibit Glycoproteins for Ebola Viral Infections - Drug Profile 193

MonoClonal Antibody for Ebola and Marburg Infections - Drug Profile 194

Monoclonal Antibody for Ebola Viral Infections - Drug Profile 195

Monoclonal Antibody for Ebola Viral Infections - Drug Profile 196

Monoclonal Antibody to Inhibit Glycoprotein for Ebola and Marburg Infections - Drug Profile 197

MV-4 - Drug Profile 198

NCK-8 - Drug Profile 199

nilotinib - Drug Profile 200

OS-2966 - Drug Profile 201

ranpirnase - Drug Profile 203

RBT-05 - Drug Profile 206

Recombinant Protein VSF for Viral Infections - Drug Profile 207

rintatolimod - Drug Profile 208

RKP-00156 - Drug Profile 217

SAB-139 - Drug Profile 218

Small Molecule 1 for Ebola Viral Infection - Drug Profile 219

Small Molecule 2 for Ebola Viral Infection - Drug Profile 220

Small Molecule for Ebola Viral Infection - Drug Profile 221

Small Molecules for Ebola and Marburg Infections - Drug Profile 222

Small Molecules for Ebola and Marburg Infections - Drug Profile 223

Small Molecules for Ebola and Marburg Virus Infections - Drug Profile 224

Small Molecules for Ebola Viral Infections - Drug Profile 225

Small Molecules for Ebola Virus Infections - Drug Profile 226

Small Molecules for Ebolavirus Infections - Drug Profile 227

Small Molecules to Inhibit Alpha-Glucosidase I and II for Viral Infections - Drug Profile 228

Small Molecules to Inhibit NPC1 for Ebola and Lassa Fever Virus - Drug Profile 229

Small Molecules to Inhibit NPC1 for Ebola Viral Infections - Drug Profile 230

Small Molecules to Inhibit Nucleoprotein for Ebola Virus Infections - Drug Profile 231

Small Molecules to Inhibit VP40 for Ebola and Marburg Viral Infections - Drug Profile 232

STP-802 - Drug Profile 233

Synthetic Peptides for Ebola Virus - Drug Profile 234

TMR-004 - Drug Profile 235

UV-4B - Drug Profile 236

V-920 - Drug Profile 237

ZMAb - Drug Profile 242

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Dormant Projects 243

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Discontinued Products 248

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Product Development Milestones 249

Featured News & Press Releases 249

Appendix 265

Methodology 265

Coverage 265

Secondary Research 265

Primary Research 265

Expert Panel Validation 265

Contact Us 265

Disclaimer 266

List of Tables

List of Tables

Number of Products under Development for Ebolavirus Infections (Ebola Hemorrhagic Fever), H2 2016 19

Number of Products under Development for Ebolavirus Infections (Ebola Hemorrhagic Fever) – Comparative Analysis, H2 2016 20

Number of Products under Development by Companies, H2 2016 21

Number of Products under Development by Companies, H2 2016 (Contd..1) 22

Number of Products under Development by Companies, H2 2016 (Contd..2) 23

Number of Products under Development by Companies, H2 2016 (Contd..3) 24

Number of Products under Investigation by Universities/Institutes, H2 2016 25

Comparative Analysis by Late Stage Development, H2 2016 26

Comparative Analysis by Clinical Stage Development, H2 2016 27

Comparative Analysis by Early Stage Development, H2 2016 28

Comparative Analysis by Unknown Stage Development, H2 2016 29

Products under Development by Companies, H2 2016 30

Products under Development by Companies, H2 2016 (Contd..1) 31

Products under Development by Companies, H2 2016 (Contd..2) 32

Products under Development by Companies, H2 2016 (Contd..3) 33

Products under Development by Companies, H2 2016 (Contd..4) 34

Products under Investigation by Universities/Institutes, H2 2016 35

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Abivax SA, H2 2016 36

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by AnGes MG Inc, H2 2016 37

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by ANP Technologies Inc, H2 2016 38

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Arno Therapeutics Inc, H2 2016 39

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by BioCryst Pharmaceuticals Inc, H2 2016 40

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by BioFactura Inc, H2 2016 41

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Celgene Corp, H2 2016 42

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Emergent BioSolutions Inc, H2 2016 43

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Enyo Pharma SAS, H2 2016 44

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Etubics Corp, H2 2016 45

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by GeoVax Labs Inc, H2 2016 46

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Gilead Sciences Inc, H2 2016 47

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by GlaxoSmithKline Plc, H2 2016 48

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Hemispherx Biopharma Inc, H2 2016 49

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Humabs BioMed SA, H2 2016 50

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Immune Response BioPharma Inc, H2 2016 51

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Immunovaccine Inc, H2 2016 52

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Inovio Pharmaceuticals Inc, H2 2016 53

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Integrated BioTherapeutics Inc, H2 2016 54

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Johnson & Johnson, H2 2016 55

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Kineta Inc, H2 2016 56

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Kymab Ltd, H2 2016 57

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Medicago Inc, H2 2016 58

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Merck & Co Inc, H2 2016 59

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Microbiotix Inc, H2 2016 60

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Micropharm Ltd, H2 2016 61

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by NanoViricides Inc, H2 2016 62

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Navigen Pharmaceuticals, Inc., H2 2016 63

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Novavax Inc, H2 2016 64

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Peregrine Pharmaceuticals Inc, H2 2016 65

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Phelix Therapeutics LLC, H2 2016 66

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by PlantForm Corp, H2 2016 67

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Profectus BioSciences Inc, H2 2016 68

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by RedHill Biopharma Ltd, H2 2016 69

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Regeneron Pharmaceuticals Inc, H2 2016 70

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Rodos BioTarget GmbH, H2 2016 71

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by SignPath Pharma Inc, H2 2016 72

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Sirnaomics Inc, H2 2016 73

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Soligenix Inc, H2 2016 74

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Taiga Biotechnologies Inc, H2 2016 75

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Tamir Biotechnology Inc, H2 2016 76

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by TGV-Laboratories, H2 2016 77

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Toyama Chemical Co Ltd, H2 2016 78

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Vaxart Inc, H2 2016 79

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by XBiotech Inc, H2 2016 80

Assessment by Monotherapy Products, H2 2016 81

Assessment by Combination Products, H2 2016 82

Number of Products by Stage and Target, H2 2016 84

Number of Products by Stage and Mechanism of Action, H2 2016 86

Number of Products by Stage and Route of Administration, H2 2016 88

Number of Products by Stage and Molecule Type, H2 2016 90

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Dormant Projects, H2 2016 250

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Dormant Projects (Contd..1), H2 2016 251

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Dormant Projects (Contd..2), H2 2016 252

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Dormant Projects (Contd..3), H2 2016 253

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Dormant Projects (Contd..4), H2 2016 254

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Discontinued Products, H2 2016 255

List of Figures

List of Figures

Number of Products under Development for Ebolavirus Infections (Ebola Hemorrhagic Fever), H2 2016 19

Number of Products under Development for Ebolavirus Infections (Ebola Hemorrhagic Fever) – Comparative Analysis, H2 2016 20

Number of Products under Development by Companies, H2 2016 21

Number of Products under Investigation by Universities/Institutes, H2 2016 25

Comparative Analysis by Clinical Stage Development, H2 2016 27

Comparative Analysis by Early Stage Products, H2 2016 28

Assessment by Monotherapy Products, H2 2016 81

Assessment by Combination Products, H2 2016 82

Number of Products by Top 10 Targets, H2 2016 83

Number of Products by Stage and Top 10 Targets, H2 2016 83

Number of Products by Top 10 Mechanism of Actions, H2 2016 85

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 85

Number of Products by Top 10 Routes of Administration, H2 2016 87

Number of Products by Stage and Top 10 Routes of Administration, H2 2016 87

Number of Products by Top 10 Molecule Types, H2 2016 89

Number of Products by Stage and Top 10 Molecule Types, H2 2016 89

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports